Pharmacy company in meningitis crisis saw contaminants
WASHINGTON (REUTERS) - The pharmacy company at the centre of a deadly meningitis outbreak knew of contamination at its Framingham, Massachusetts facility as early as January but has no record of acting to safeguard the drugs prepared there, United States (US) health officials said on Friday.
A report by the Food and Drug Administration (FDA) showed that internal monitoring at the New England Compounding Centre (NECC) had repeatedly detected bacterial and mold contaminations in the months before the first suspect shipments of injectable steroid treatments left the production site in May.
NECC said in a statement that it had received a copy of the report and would provide comments to health officials after reviewing the document.
The report, known as an FDA Form 483, contained findings collected by NECC's environmental monitoring programme from January to September, as well as observations from several October inspections conducted by FDA and Massachusetts state officials.